Medindia

X

Myconostica Attains CE Mark for MycAssay(TM) Aspergillus

Wednesday, October 14, 2009 General News J E 4
Advertisement
LONDON, October 14 Myconostica Ltd, a UK-based medical diagnostic company which specialisesin rapid molecular diagnostic tests for life-threatening fungal infections,today announces the launch of a new test to assist medical and scientificprofessionals to identify one of the most common causes of fungal pneumonia.The assay, MycAssay(TM) Aspergillus, is a real-time PCR test which accuratelyand rapidly identifies infections caused by Aspergillus.

MycAssay(TM) Aspergillus is a sensitive and specific assay designed to aid healthcare professionals involved in the diagnosis of Aspergillus infections. Pneumonia caused by Aspergillus is the leading cause of infectious death in leukaemia and bone marrow patients with an estimated 10 million people at risk globally each year. Studies have shown that diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90% to 40% thus highlighting the necessity of rapid diagnostic testing.

Traditional methods used to identify Aspergillus infections arewell-documented as being inaccurate, insensitive and slow, with a resulttaking up to 10 days. When MycAssay(TM) Aspergillus is combined withMyconostica's fungal DNA extraction system, MycXtra(R), a result can beobtained within 3 hours therefore providing a rapid, sensitive and specificalternative to the conventional techniques used to identify Aspergillusinfections.

MycAssay(TM) Aspergillus is the latest in a pipeline of products fromMyconostica designed to assist in the diagnosis of fungal disease. MycAssay(TM) Pneumocystis, for the detection of infections caused by Pneumocystis jirovecii was launched earlier this year and further tests in the MycAssay(TM) series will also target critical fungal infections, such as Candida.

Commenting on the launch of MycAssay(TM) Aspergillus, Dr. John Thornback,Chief Operating Officer of Myconostica said:

"Early diagnosis of invasive fungal infection significantly improves thechances of survival. This new test from Myconostica will allow healthcareprofessionals to rapidly identify samples containing Aspergillus DNA fromthose patients infected by Aspergillus, aiding clinicians to prescribeappropriate drugs to treat the infection. Early identification of disease hasbeen shown to reduce the patient's exposure to inappropriate drug treatments,improves patient outcomes and reduces the hospitalisation and treatment costsassociated with invasive fungal disease'.

About Myconostica Ltd

Myconostica Ltd, a UK-based medical diagnostic company specialises inrapid molecular diagnostic tests for life-threatening fungal infections.Traditional methods of the detection of fungal infections are well documentedas being relatively insensitive and slow. Tests provided by Myconostica aimto allow healthcare professionals to rapidly identify patients infected thusenabling clinicians to prescribe appropriate drug therapy. Myconostica isdeveloping and commercialising a portfolio of real-time molecular diagnostictests for life-threatening fungal infections. Over 10 million people are atrisk of these infections each year in Europe and North America alone.

For further information: Myconostica Ltd. Dr. Francesca Sadler Sales and Marketing Manager Tel: +44-161-998-7239 mycoinfo@myconostica.co.uk http://www.myconostica.co.uk Media Enquiries: Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44(0)20-7930-0777



For further information: Myconostica Ltd. Dr. Francesca Sadler, Sales and Marketing Manager, Tel: +44-161-998-7239, mycoinfo@myconostica.co.uk; Media Enquiries: Cardew Group, Tim Robertson/ Jamie Milton/ Matthew Law, +44(0)20-7930-0777
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Irvine Scientific and Selexis to Announce Results ...
S
Global Bioenergies is Setting-Up its Scientific Ad...